Antonio J Grillo-López
Rancho Research Institute(US)
Publications by Year
Research Areas
Lymphoma Diagnosis and Treatment, Monoclonal and Polyclonal Antibodies Research, Chronic Lymphocytic Leukemia Research, Radiopharmaceutical Chemistry and Applications, Health Systems, Economic Evaluations, Quality of Life
Most-Cited Works
- → Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas(1999)3,489 cited
- → IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma(1997)1,692 cited
- → Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma(2002)1,164 cited
- → Rituximab Anti-CD20 Monoclonal Antibody Therapy in Non-Hodgkin’s Lymphoma: Safety and Efficacy of Re-Treatment(2000)688 cited
- → Phase I/II Trial of IDEC-Y2B8 Radioimmunotherapy for Treatment of Relapsed or Refractory CD20+B-Cell Non-Hodgkin's Lymphoma(1999)538 cited
- → Rituximab Using A Thrice Weekly Dosing Schedule in B-Cell Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Demonstrates Clinical Activity and Acceptable Toxicity(2001)511 cited
- → Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment(2002)420 cited
- → Prolonged Clinical and Molecular Remission in Patients With Low-Grade or Follicular Non-Hodgkin's Lymphoma Treated With Rituximab Plus CHOP Chemotherapy: 9-Year Follow-Up(2004)364 cited
- Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma.(1996)
- → Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial(2002)266 cited